Arturo Estrella has a message for recession naysayers: It could hit sooner than you think.Marketsread more
Local governments commonly share single service providers, making many vulnerable at once. On top of this, ransomware has often been used to mask more targeted, malicious...Technologyread more
Salesforce released its first earnings report since its $15.3 billion acquisition of Tableau Software, the company's largest deal ever.Technologyread more
Fed Chairman Jerome Powell faces the tough challenge of presenting a unified voice on Fed policy from the most divided Fed in years.Market Insiderread more
Kudlow also confirmed to CNBC that he supported a tax cut proposal floated earlier Thursday by Sen. Rick Scott, R-Fla.Politicsread more
VMware is following through on its proposal to buy Pivotal, a fellow Dell subsidiary, and expanding into cybersecurity with the acquisition of Carbon Black.Technologyread more
Google says it shut down hundreds of YouTube channels tied to misinformation around the Hong Kong protests.Technologyread more
It is a rare scenario where long-term interest rates suddenly fall below short-term interest rates.Real Estateread more
Investors are rushing to get a piece of its privately held rival Impossible Foods before it goes public, according to the Wall Street Journal.Food & Beverageread more
Weisler has been CEO at the company since 2015 when it split from HPE.Technologyread more
Companies want to know our values and if they work with us, "they want to be aligned with those values," Salesforce co-CEO Keith Block says.Mad Money with Jim Cramerread more
Gilead CEO John Milligan called on the pharmaceutical industry to do more amid criticism of drug pricing.
"I think we've done a bad job as an industry of being transparent. We haven't really talked about what is paid by the payer or paid by the patient," Milligan said on CNBC's "Fast Money " on Tuesday.
The biotech industry has been under intense scrutiny amid criticism from presidential hopefuls in the past year.
Sen. Bernie Sanders has called out individual pharmaceutical companies for raising prices on orphan drugs. Hillary Clinton was also vocal about the issue, taking down the price of a key biotech ETF in the wake of her comments. President-elect Donald Trump told Time magazine that he wants to bring down drug prices because he doesn't like what has happened with them.
The payment system in the United States is fragmented, which Milligan said "creates a disconnect between the price that's often published and the price that people pay." The Gilead CEO added he believes there's too much burden placed on the patient in the current system.